Human Insulin Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)

Description

In the relentless battle against diabetes, the global human insulin market is poised for significant growth. With an estimated value of US$ 45 billion in 2024, this vital sector is projected to soar to US$ 75 billion by 2031, boasting a robust compound annual growth rate (CAGR) of 8%. The prevalence of diabetes, particularly in North America, the Asia-Pacific, Europe, and LATAM regions, underscores the urgent need for advanced insulin solutions.

According to the Centers for Disease Control and Prevention (CDC), over 30 million individuals in the US grapple with diabetes, with a staggering 23 million diagnosed cases. Internationally, the International Diabetes Federation reports that more than 400 million people worldwide suffer from this condition. Notably, while diabetes type 1 is prevalent in North America and the Asia-Pacific, Europe and LATAM are confronted with diabetes type 2. Alarmingly, sedentary lifestyles have expanded the demographic of diabetic patients, including younger individuals, contributing to the burgeoning demand for effective insulin treatments.

Factors Restraining Market Growth

Despite the promising trajectory, the human insulin market faces formidable challenges. Uneven pricing and limited access in emerging economies hinder market expansion, compounded by stringent regulatory hurdles for drug approvals. Delays in the approval process disrupt the demand-supply equilibrium, posing further constraints to market growth.

Dominance of Modern Human Insulin

"Modernization to hold the flag high"

Modern human insulin commands over 80% of the market share, underpinned by relentless research endeavors driving innovation in treatment modalities. Insulin analogues, biosimilars, and human insulin biologics, administered through various delivery devices such as pens, pen needles, and syringes, constitute the cornerstone of modern insulin therapies. Despite the enduring relevance of traditional human insulin, the escalating global diabetic population underscores the indispensability of modern insulin to meet growing demands.

Impact of Covid-19

"End-customers turning out to be more cautious"

The Covid-19 pandemic has precipitated seismic shifts in healthcare dynamics, compelling individuals with chronic conditions like diabetes to adopt heightened vigilance. With diabetes patients at increased risk of Covid-19 complications, a dual focus on disease management and pandemic mitigation strategies has emerged. Consequently, the pursuit of stronger measures to control diabetes serves as a preemptive defense against Covid-19, driving market demand for innovative insulin solutions.

Competitive Landscape and Key Players

Innovation remains the cornerstone of competitiveness in the human insulin market, with key players such as Novo Nordisk A/S, Eli Lilly and Company, Sanofi, and Biocon spearheading advancements in modern insulin therapies. As modern human insulin continues to dominate the market, the competitive landscape is characterized by a relentless pursuit of innovation to address evolving healthcare needs.

Key Companies Profiled in the market include:

Novo Nordisk A/S.
Eli Lilly and Company.
Sanofi.
Biocon.
Tonghua Dongbao Pharmaceutical Co., Ltd.
Adocia, Merck & Co., Inc.
Pfizer, Inc.
Wockhardt.
Julphar.
Bristol-Myers Squibb Company.
GlaxoSmithKline Plc.
Oramed Pharmaceuticals, Inc.

Key Segments Covered in Human Insulin Market

Human Insulin Market by Type

Modern Human Insulin
- Fast-acting
- Long-acting
- Premix
Traditional Human Insulin
- Long-acting
- Short-acting
- Fast-acting
- Premix

Human Insulin Market by Distribution Channel

Retail Pharmacies
Hospital Pharmacies
Online Pharmacies

Human Insulin Market by Type of Diabetes

Diabetes Type 1
Diabetes Type 2

Human Insulin by Region

North America Human Insulin Market
Latin America Human Insulin Market
Europe Human Insulin Market
Asia-Pacific Human Insulin Market
Middle East & Africa (MEA) Human Insulin Market

1. Executive Summary

1.1. Global Human Insulin Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations

2. Market Overview

2.1. Market Definitions and Segmentations
2.2. Market Dynamics
- 2.2.1. Drivers
- 2.2.2. Restraints
- 2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
- 2.5.1. Supply
- 2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
- 2.7.1. World Economic Projections
2.8. PESTLE Analysis

3. Global Human Insulin Market Outlook, 2018 - 2031

3.1. Global Human Insulin Market Outlook, by Type, Value (US$ Bn), 2018 - 2031
- 3.1.1. Key Highlights
  - 3.1.1.1. Modern Human Insulin
    - 3.1.1.1.1. Fast-acting
    - 3.1.1.1.2. Long-acting
    - 3.1.1.1.3. Premix
  - 3.1.1.2. Traditional Human Insulin
    - 3.1.1.2.1. Long-acting
    - 3.1.1.2.2. Short-acting
    - 3.1.1.2.3. Fast-acting
    - 3.1.1.2.4. Premix
3.2. Global Human Insulin Market Outlook, by Type of Diabetes, Value (US$ Bn), 2018 - 2031
- 3.2.1. Key Highlights
  - 3.2.1.1. Diabetes Type 1
  - 3.2.1.2. Diabetes Type 2
3.3. Global Human Insulin Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 3.3.1. Key Highlights
  - 3.3.1.1. Retail Pharmacies
  - 3.3.1.2. Hospital Pharmacies
  - 3.3.1.3. Online Pharmacies
3.4. Global Human Insulin Market Outlook, by Region, Value (US$ Bn), 2018 - 2031
- 3.4.1. Key Highlights
  - 3.4.1.1. North America
  - 3.4.1.2. Europe
  - 3.4.1.3. Asia Pacific
  - 3.4.1.4. Latin America
  - 3.4.1.5. Middle East & Africa

4. North America Human Insulin Market Outlook, 2018 - 2031

4.1. North America Human Insulin Market Outlook, by Type, Value (US$ Bn), 2018 - 2031
- 4.1.1. Key Highlights
  - 4.1.1.1. Modern Human Insulin
    - 4.1.1.1.1. Fast-acting
    - 4.1.1.1.2. Long-acting
    - 4.1.1.1.3. Premix
  - 4.1.1.2. Traditional Human Insulin
    - 4.1.1.2.1. Long-acting
    - 4.1.1.2.2. Short-acting
    - 4.1.1.2.3. Fast-acting
    - 4.1.1.2.4. Premix
4.2. North America Human Insulin Market Outlook, by Type of Diabetes, Value (US$ Bn), 2018 - 2031
- 4.2.1. Key Highlights
  - 4.2.1.1. Diabetes Type 1
  - 4.2.1.2. Diabetes Type 2
4.3. North America Human Insulin Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 4.3.1. Key Highlights
  - 4.3.1.1. Retail Pharmacies
  - 4.3.1.2. Hospital Pharmacies
  - 4.3.1.3. Online Pharmacies
- 4.3.2. BPS Analysis/Market Attractiveness Analysis
4.4. North America Human Insulin Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 4.4.1. Key Highlights
  - 4.4.1.1. U.S. Human Insulin Market by Type, Value (US$ Bn), 2018 - 2031
  - 4.4.1.2. U.S. Human Insulin Market by Type of Diabetes, Value (US$ Bn), 2018 - 2031
  - 4.4.1.3. U.S. Human Insulin Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 4.4.1.4. Canada Human Insulin Market by Type, Value (US$ Bn), 2018 - 2031
  - 4.4.1.5. Canada Human Insulin Market by Type of Diabetes, Value (US$ Bn), 2018 - 2031
  - 4.4.1.6. Canada Human Insulin Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Human Insulin Market Outlook, 2018 - 2031

5.1. Europe Human Insulin Market Outlook, by Type, Value (US$ Bn), 2018 - 2031
- 5.1.1. Key Highlights
  - 5.1.1.1. Modern Human Insulin
    - 5.1.1.1.1. Fast-acting
    - 5.1.1.1.2. Long-acting
    - 5.1.1.1.3. Premix
  - 5.1.1.2. Traditional Human Insulin
    - 5.1.1.2.1. Long-acting
    - 5.1.1.2.2. Short-acting
    - 5.1.1.2.3. Fast-acting
    - 5.1.1.2.4. Premix
5.2. Europe Human Insulin Market Outlook, by Type of Diabetes, Value (US$ Bn), 2018 - 2031
- 5.2.1. Key Highlights
  - 5.2.1.1. Diabetes Type 1
  - 5.2.1.2. Diabetes Type 2
5.3. Europe Human Insulin Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 5.3.1. Key Highlights
  - 5.3.1.1. Retail Pharmacies
  - 5.3.1.2. Hospital Pharmacies
  - 5.3.1.3. Online Pharmacies
- 5.3.2. BPS Analysis/Market Attractiveness Analysis
5.4. Europe Human Insulin Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 5.4.1. Key Highlights
  - 5.4.1.1. Germany Human Insulin Market by Type, Value (US$ Bn), 2018 - 2031
  - 5.4.1.2. Germany Human Insulin Market by Type of Diabetes, Value (US$ Bn), 2018 - 2031
  - 5.4.1.3. Germany Human Insulin Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.4.1.4. U.K. Human Insulin Market by Type, Value (US$ Bn), 2018 - 2031
  - 5.4.1.5. U.K. Human Insulin Market by Type of Diabetes, Value (US$ Bn), 2018 - 2031
  - 5.4.1.6. U.K. Human Insulin Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.4.1.7. France Human Insulin Market by Type, Value (US$ Bn), 2018 - 2031
  - 5.4.1.8. France Human Insulin Market by Type of Diabetes, Value (US$ Bn), 2018 - 2031
  - 5.4.1.9. France Human Insulin Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.4.1.10. Italy Human Insulin Market by Type, Value (US$ Bn), 2018 - 2031
  - 5.4.1.11. Italy Human Insulin Market by Type of Diabetes, Value (US$ Bn), 2018 - 2031
  - 5.4.1.12. Italy Human Insulin Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.4.1.13. Turkey Human Insulin Market by Type, Value (US$ Bn), 2018 - 2031
  - 5.4.1.14. Turkey Human Insulin Market by Type of Diabetes, Value (US$ Bn), 2018 - 2031
  - 5.4.1.15. Turkey Human Insulin Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.4.1.16. Russia Human Insulin Market by Type, Value (US$ Bn), 2018 - 2031
  - 5.4.1.17. Russia Human Insulin Market by Type of Diabetes, Value (US$ Bn), 2018 - 2031
  - 5.4.1.18. Russia Human Insulin Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 5.4.1.19. Rest of Europe Human Insulin Market by Type, Value (US$ Bn), 2018 - 2031
  - 5.4.1.20. Rest of Europe Human Insulin Market by Type of Diabetes, Value (US$ Bn), 2018 - 2031
  - 5.4.1.21. Rest of Europe Human Insulin Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Human Insulin Market Outlook, 2018 - 2031

6.1. Asia Pacific Human Insulin Market Outlook, by Type, Value (US$ Bn), 2018 - 2031
- 6.1.1. Key Highlights
  - 6.1.1.1. Modern Human Insulin
    - 6.1.1.1.1. Fast-acting
    - 6.1.1.1.2. Long-acting
    - 6.1.1.1.3. Premix
  - 6.1.1.2. Traditional Human Insulin
    - 6.1.1.2.1. Long-acting
    - 6.1.1.2.2. Short-acting
    - 6.1.1.2.3. Fast-acting
    - 6.1.1.2.4. Premix
6.2. Asia Pacific Human Insulin Market Outlook, by Type of Diabetes, Value (US$ Bn), 2018 - 2031
- 6.2.1. Key Highlights
  - 6.2.1.1. Diabetes Type 1
  - 6.2.1.2. Diabetes Type 2
6.3. Asia Pacific Human Insulin Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 6.3.1. Key Highlights
  - 6.3.1.1. Retail Pharmacies
  - 6.3.1.2. Hospital Pharmacies
  - 6.3.1.3. Online Pharmacies
- 6.3.2. BPS Analysis/Market Attractiveness Analysis
6.4. Asia Pacific Human Insulin Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 6.4.1. Key Highlights
  - 6.4.1.1. China Human Insulin Market by Type, Value (US$ Bn), 2018 - 2031
  - 6.4.1.2. China Human Insulin Market by Type of Diabetes, Value (US$ Bn), 2018 - 2031
  - 6.4.1.3. China Human Insulin Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.4.1.4. Japan Human Insulin Market by Type, Value (US$ Bn), 2018 - 2031
  - 6.4.1.5. Japan Human Insulin Market by Type of Diabetes, Value (US$ Bn), 2018 - 2031
  - 6.4.1.6. Japan Human Insulin Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.4.1.7. South Korea Human Insulin Market by Type, Value (US$ Bn), 2018 - 2031
  - 6.4.1.8. South Korea Human Insulin Market by Type of Diabetes, Value (US$ Bn), 2018 - 2031
  - 6.4.1.9. South Korea Human Insulin Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.4.1.10. India Human Insulin Market by Type, Value (US$ Bn), 2018 - 2031
  - 6.4.1.11. India Human Insulin Market by Type of Diabetes, Value (US$ Bn), 2018 - 2031
  - 6.4.1.12. India Human Insulin Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.4.1.13. Southeast Asia Human Insulin Market by Type, Value (US$ Bn), 2018 - 2031
  - 6.4.1.14. Southeast Asia Human Insulin Market by Type of Diabetes, Value (US$ Bn), 2018 - 2031
  - 6.4.1.15. Southeast Asia Human Insulin Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 6.4.1.16. Rest of Asia Pacific Human Insulin Market by Type, Value (US$ Bn), 2018 - 2031
  - 6.4.1.17. Rest of Asia Pacific Human Insulin Market by Type of Diabetes, Value (US$ Bn), 2018 - 2031
  - 6.4.1.18. Rest of Asia Pacific Human Insulin Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Human Insulin Market Outlook, 2018 - 2031

7.1. Latin America Human Insulin Market Outlook, by Type, Value (US$ Bn), 2018 - 2031
- 7.1.1. Key Highlights
  - 7.1.1.1. Modern Human Insulin
    - 7.1.1.1.1. Fast-acting
    - 7.1.1.1.2. Long-acting
    - 7.1.1.1.3. Premix
  - 7.1.1.2. Traditional Human Insulin
    - 7.1.1.2.1. Long-acting
    - 7.1.1.2.2. Short-acting
    - 7.1.1.2.3. Fast-acting
    - 7.1.1.2.4. Premix
7.2. Latin America Human Insulin Market Outlook, by Type of Diabetes, Value (US$ Bn), 2018 - 2031
- 7.2.1. Key Highlights
  - 7.2.1.1. Diabetes Type 1
  - 7.2.1.2. Diabetes Type 2
7.3. Latin America Human Insulin Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 7.3.1. Key Highlights
  - 7.3.1.1. Retail Pharmacies
  - 7.3.1.2. Hospital Pharmacies
  - 7.3.1.3. Online Pharmacies
- 7.3.2. BPS Analysis/Market Attractiveness Analysis
7.4. Latin America Human Insulin Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 7.4.1. Key Highlights
  - 7.4.1.1. Brazil Human Insulin Market by Type, Value (US$ Bn), 2018 - 2031
  - 7.4.1.2. Brazil Human Insulin Market by Type of Diabetes, Value (US$ Bn), 2018 - 2031
  - 7.4.1.3. Brazil Human Insulin Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 7.4.1.4. Mexico Human Insulin Market by Type, Value (US$ Bn), 2018 - 2031
  - 7.4.1.5. Mexico Human Insulin Market by Type of Diabetes, Value (US$ Bn), 2018 - 2031
  - 7.4.1.6. Mexico Human Insulin Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 7.4.1.7. Argentina Human Insulin Market by Type, Value (US$ Bn), 2018 - 2031
  - 7.4.1.8. Argentina Human Insulin Market by Type of Diabetes, Value (US$ Bn), 2018 - 2031
  - 7.4.1.9. Argentina Human Insulin Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 7.4.1.10. Rest of Latin America Human Insulin Market by Type, Value (US$ Bn), 2018 - 2031
  - 7.4.1.11. Rest of Latin America Human Insulin Market by Type of Diabetes, Value (US$ Bn), 2018 - 2031
  - 7.4.1.12. Rest of Latin America Human Insulin Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Human Insulin Market Outlook, 2018 - 2031

8.1. Middle East & Africa Human Insulin Market Outlook, by Type, Value (US$ Bn), 2018 - 2031
- 8.1.1. Key Highlights
  - 8.1.1.1. Modern Human Insulin
    - 8.1.1.1.1. Fast-acting
    - 8.1.1.1.2. Long-acting
    - 8.1.1.1.3. Premix
  - 8.1.1.2. Traditional Human Insulin
    - 8.1.1.2.1. Long-acting
    - 8.1.1.2.2. Short-acting
    - 8.1.1.2.3. Fast-acting
    - 8.1.1.2.4. Premix
8.2. Middle East & Africa Human Insulin Market Outlook, by Type of Diabetes, Value (US$ Bn), 2018 - 2031
- 8.2.1. Key Highlights
  - 8.2.1.1. Diabetes Type 1
  - 8.2.1.2. Diabetes Type 2
8.3. Middle East & Africa Human Insulin Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 8.3.1. Key Highlights
  - 8.3.1.1. Retail Pharmacies
  - 8.3.1.2. Hospital Pharmacies
  - 8.3.1.3. Online Pharmacies
- 8.3.2. BPS Analysis/Market Attractiveness Analysis
8.4. Middle East & Africa Human Insulin Market Outlook, by Country, Value (US$ Bn), 2018 - 2031
- 8.4.1. Key Highlights
  - 8.4.1.1. GCC Human Insulin Market by Type, Value (US$ Bn), 2018 - 2031
  - 8.4.1.2. GCC Human Insulin Market by Type of Diabetes, Value (US$ Bn), 2018 - 2031
  - 8.4.1.3. GCC Human Insulin Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.4.1.4. South Africa Human Insulin Market by Type, Value (US$ Bn), 2018 - 2031
  - 8.4.1.5. South Africa Human Insulin Market by Type of Diabetes, Value (US$ Bn), 2018 - 2031
  - 8.4.1.6. South Africa Human Insulin Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.4.1.7. Egypt Human Insulin Market by Type, Value (US$ Bn), 2018 - 2031
  - 8.4.1.8. Egypt Human Insulin Market by Type of Diabetes, Value (US$ Bn), 2018 - 2031
  - 8.4.1.9. Egypt Human Insulin Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.4.1.10. Nigeria Human Insulin Market by Type, Value (US$ Bn), 2018 - 2031
  - 8.4.1.11. Nigeria Human Insulin Market by Type of Diabetes, Value (US$ Bn), 2018 - 2031
  - 8.4.1.12. Nigeria Human Insulin Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
  - 8.4.1.13. Rest of Middle East & Africa Human Insulin Market by Type, Value (US$ Bn), 2018 - 2031
  - 8.4.1.14. Rest of Middle East & Africa Human Insulin Market by Type of Diabetes, Value (US$ Bn), 2018 - 2031
  - 8.4.1.15. Rest of Middle East & Africa Human Insulin Market by Distribution Channel, Value (US$ Bn), 2018 - 2031
- 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

9.1. By Type vs Distribution Channel Heatmap
9.2. Company Market Share Analysis, 2023
9.3. Competitive Dashboard
9.4. Company Profiles
- 9.4.1. Novo Nordisk A/S.
  - 9.4.1.1. Company Overview
  - 9.4.1.2. Product Portfolio
  - 9.4.1.3. Financial Overview
  - 9.4.1.4. Business Strategies and Development
- 9.4.2. Eli Lilly and Company.
  - 9.4.2.1. Company Overview
  - 9.4.2.2. Product Portfolio
  - 9.4.2.3. Financial Overview
  - 9.4.2.4. Business Strategies and Development
- 9.4.3. Sanofi.
  - 9.4.3.1. Company Overview
  - 9.4.3.2. Product Portfolio
  - 9.4.3.3. Financial Overview
  - 9.4.3.4. Business Strategies and Development
- 9.4.4. Biocon.
  - 9.4.4.1. Company Overview
  - 9.4.4.2. Product Portfolio
  - 9.4.4.3. Financial Overview
  - 9.4.4.4. Business Strategies and Development
- 9.4.5. Tonghua Dongbao Pharmaceutical Co., Ltd.
  - 9.4.5.1. Company Overview
  - 9.4.5.2. Product Portfolio
  - 9.4.5.3. Financial Overview
  - 9.4.5.4. Business Strategies and Development
- 9.4.6. Adocia, Merck & Co., Inc.
  - 9.4.6.1. Company Overview
  - 9.4.6.2. Product Portfolio
  - 9.4.6.3. Financial Overview
  - 9.4.6.4. Business Strategies and Development
- 9.4.7. Pfizer, Inc.
  - 9.4.7.1. Company Overview
  - 9.4.7.2. Product Portfolio
  - 9.4.7.3. Financial Overview
  - 9.4.7.4. Business Strategies and Development
- 9.4.8. Wockhardt.
  - 9.4.8.1. Company Overview
  - 9.4.8.2. Product Portfolio
  - 9.4.8.3. Financial Overview
  - 9.4.8.4. Business Strategies and Development
- 9.4.9. Julphar.
  - 9.4.9.1. Company Overview
  - 9.4.9.2. Product Portfolio
  - 9.4.9.3. Financial Overview
  - 9.4.9.4. Business Strategies and Development
- 9.4.10. Bristol-Myers Squibb Company.
  - 9.4.10.1. Company Overview
  - 9.4.10.2. Product Portfolio
  - 9.4.10.3. Financial Overview
  - 9.4.10.4. Business Strategies and Development
- 9.4.11. GlaxoSmithKline Plc.
  - 9.4.11.1. Company Overview
  - 9.4.11.2. Product Portfolio
  - 9.4.11.3. Financial Overview
  - 9.4.11.4. Business Strategies and Development
- 9.4.12. Oramed Pharmaceuticals, Inc.
  - 9.4.12.1. Company Overview
  - 9.4.12.2. Product Portfolio
  - 9.4.12.3. Financial Overview
  - 9.4.12.4. Business Strategies and Development

10. Appendix

10.1. Research Methodology
10.2. Report Assumptions
10.3. Acronyms and Abbreviations